GALECTO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7048 USD | +5.37% |
|
+3.42% | -2.11% |
| Mar. 08 | Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Galecto Shares Climb After Bone Marrow Disease Treatment Trial Yields Positive Results | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 19.11M |
|---|---|---|---|---|---|
| Net income 2024 * | -32M | Net income 2025 * | -52M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 18.1M | Net cash position 2025 * | 71.7M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.59
x | P/E ratio 2025 * |
-0.39
x | Employees | 13 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.19% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +5.37% | ||
| 1 week | +3.42% | ||
| Current month | -9.64% | ||
| 1 month | -6.59% | ||
| 3 months | +5.19% | ||
| 6 months | +28.12% | ||
| Current year | -2.11% |
1 week
0.65
0.72
1 month
0.600.82
Current year
0.560.94
1 year
0.503.70
3 years
0.5016.41
5 years
0.5017.99
10 years
0.5017.99
| Managers | Title | Age | Since |
|---|---|---|---|
Hans Schambye
CEO | Chief Executive Officer | 59 | 10-12-31 |
Jonathan Freve
DFI | Director of Finance/CFO | 46 | 20-03-31 |
Anders Pedersen
COO | Chief Operating Officer | 64 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 65 | 19-12-31 | |
Chau Khuong
BRD | Director/Board Member | 48 | 17-12-31 |
David Shapiro
BRD | Director/Board Member | 69 | 20-05-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.7048 | +5.37% | 119,427 |
| 24-04-25 | 0.6689 | -0.31% | 26,490 |
| 24-04-24 | 0.671 | -4.22% | 75,622 |
| 24-04-23 | 0.7006 | +2.88% | 107,064 |
| 24-04-22 | 0.681 | -0.07% | 61,562 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm EDT
More quotes
Galecto, Inc. is a clinical-stage biotechnology company. The Company is focused on developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Companyâs initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). It is developing GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Companyâs product candidate also includes GB1211, a selective oral small molecule inhibitor of galectin-three, is chemically distinct from GB0139 and is being developed for the treatment of various oncology indications and liver cirrhosis, and GB2064 is a selective oral small molecule inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which progressive fibrosis reduces the ability to form blood cells in the bone marrow.
Calendar
2024-07-30
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.7048
USD
Average target price
6
USD
Spread / Average Target
+751.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.11% | 19.11M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- GLTO Stock
